Nektar Therapeutics Given Buy Rating at Jefferies Group (NKTR)
Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group in a research report issued to clients and investors on Tuesday, AnalystRatingsNetwork reports. They currently have a $15.00 price objective on the stock. Jefferies Group’s price target points to a potential upside of 30.55% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at MKM Partners downgraded shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, February 27th. They now have a $13.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks downgraded shares of Nektar Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 5th. They now have a $14.90 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Nektar Therapeutics from $14.00 to $18.00 in a research note on Monday, February 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $15.99.
Nektar Therapeutics (NASDAQ:NKTR) traded up 2.68% on Tuesday, hitting $11.49. 1,100,605 shares of the company’s stock traded hands. Nektar Therapeutics has a 52-week low of $8.72 and a 52-week high of $15.34. The stock has a 50-day moving average of $12.15 and a 200-day moving average of $11.98. The company’s market cap is $1.455 billion.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.24. The company had revenue of $31.15 million for the quarter, compared to the consensus estimate of $49.26 million. The company’s revenue for the quarter was up 47.3% on a year-over-year basis. On average, analysts predict that Nektar Therapeutics will post $-0.62 earnings per share for the current fiscal year.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.